SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of SB-715992 in treating
patients with metastatic or unresectable solid tumors or Hodgkin's or non-Hodgkin's lymphoma.
Drugs used in chemotherapy, such as SB-715992, work in different ways to stop the growth of
cancer cells, either by killing the cells or by stopping them from dividing